文献速递MDS 与骨髓增殖性肿瘤造血干细胞移植与细胞治疗

无关供者移植后环磷酰胺与抗胸腺细胞球蛋白预防移植物抗宿主病在骨髓增生异常肿瘤中的比较

Unrelated donor transplantation with posttransplant cyclophosphamide vs ATG for myelodysplastic neoplasms.
PubMed 文献 · Blood Adv · 2024-01-01

该研究基于欧洲血液与骨髓移植学会登记组数据,纳入960例接受无关供者异基因造血干细胞移植的骨髓增生异常肿瘤患者,比较移植后环磷酰胺(PTCY)与抗胸腺细胞球蛋白(ATG)预防移植物抗宿主病(GVHD)的结局。中位随访4.4年,PTCY组5年总生存率58%高于ATG组49%,5年无进展生存率53%高于ATG组44%,2至4级急性GVHD发生率PTCY组23%更低,5年慢性GVHD发生率无差异。研究提示在此情境下以PTCY替代ATG进行GVHD预防仍是有效选择,但需进一步前瞻性随机研究确认。

要点

  • 中位随访4.4年,PTCY组5年OS 58% vs ATG组49%,5年PFS 53% vs 44%。
  • 第28天中性粒细胞植入ATG组93%优于PTCY组85%。
  • 2至4级急性GVHD发生率PTCY组23%更低,5年慢性GVHD发生率无差异。

核心结论

  • 该研究提示,在无关供者异基因造血干细胞移植中,以PTCY替代ATG进行GVHD预防仍是有效选择。
  • 原文结论指出,需进一步前瞻性随机研究以确认这些结果。

研究设计与样本

  • 研究为欧洲血液与骨髓移植学会登记组数据的分析,纳入960例接受无关供者异基因造血干细胞移植的骨髓增生异常肿瘤患者,以PTCY或ATG作为GVHD预防。
  • 主要结局为总生存(OS)和无进展生存(PFS)。

主要发现

  • 两组疾病特征相似。
  • 第28天中性粒细胞植入ATG组为93%,PTCY组为85%。
  • 中位随访4.4年,5年OS在PTCY组为58%,ATG组为49%;5年PFS在PTCY组为53%,ATG组为44%。
  • 2至4级急性GVHD发生率在使用PTCY时为23%,更低;5年慢性GVHD发生率无差异。

局限性

  • 原文结论指出,需进一步前瞻性随机研究以确认这些结果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

It has been reported in prospective randomized trials that antithymocyte globulin (ATG)-based graft-versus-host disease (GVHD) prophylaxis has benefits in the setting of allogeneic hematopoietic stem cell transplantation (allo-HSCT) with unrelated donors (UDs). However, the optimal GVHD prophylaxis strategy has been challenged recently by the increasing use of posttransplant cyclophosphamide (PTCY). We report from the European Society for Blood and Marrow Transplantation registry the outcomes of 960 patients with myelodysplastic neoplasms who underwent allo-HSCT from UD with PTCY or ATG as GVHD prophylaxis. The primary outcomes were overall survival (OS) and progression-free survival (PFS). The disease characteristics were similar in both groups. Day 28 neutrophil engraftment was significantly better with ATG (93% vs 85%). Over a median follow-up of 4.4 years, the 5-year OS was 58% with PTCY, and 49% in the ATG group. The 5-year PFS was higher for PTCY at 53% vs 44% for ATG. Grade 2 to 4 acute GVHD incidence was lower when PTCY was used (23%), whereas there was no difference in the incidence of chronic GVHD at 5 years. Multivariable analyses confirmed better OS and PFS with PTCY with a hazard ratio (HR) for ATG of 1.32 (1-1.74) and a better PFS for PTCY with a HR for ATG of 1.33. This study suggests that GVHD prophylaxis using PTCY instead of ATG in this setting remains a valid option. Further prospective randomized studies would be essential to confirm these results.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Chalandon Y, Eikema DJ, Moiseev I, et al. Unrelated donor transplantation with posttransplant cyclophosphamide vs ATG for myelodysplastic neoplasms. Blood Adv. 2024. PMID: 39008719. doi:10.1182/bloodadvances.2024013468

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。